Zydus Lifesciences Limited (Formerly known as Cadila Healthcare Limited ... There is currently no vaccine to prevent or medicine to treat chikungunya virus infection.On 30 September 2016, Cadila ...

Zydus has announced that the USFDA has granted Orphan Drug Designation (ODD) to Usnoflast, a novel oral NLRP3 inhibitor, for the treatment of amyotrophic lateral sclerosis (ALS). The designation ...

Zydus Lifesciences announced that Usnoflast, a treatment for amyotrophic lateral sclerosis (ALS), has received Orphan Drug Designation from the US FDA. This designation supports the development of ...

The US Food and Drug Administration (FDA) has granted approval for Zydus Lifesciences to proceed with a randomised Phase IIb trial of its oral NLRP3 inflammasome inhibitor, Usnoflast, for ...

Zydus, a leading, discovery-based, global pharmaceutical company announced that the US FDA has granted Orphan Drug Designation (ODD) to Usnoflast, a novel oral NLRP3 inhibitor, for the treatment of ...

The US Food and Drug Administration (FDA) has granted approval for Zydus Lifesciences to proceed with a randomised Phase IIb ...

Saint Louis University's School of Medicine has a long tradition of excellence in medical school, graduate medical education and graduate education. Established in 1836, the school has the distinction ...

Doctors and their patients discuss the range of services that Duke Cancer Institute provides to teens and younger adults with a history of cancer. Beyond Cancer: Mental Health and Therapy Duke ...

Duke clinicians and patients discuss how approaches such as talk, music, and art therapy can address psychosocial issues that cancer survivors often face. Beyond Cancer: Building Bridges Experts ...

Forcing a struggling child to take any medicine can lead to vomiting or choking. Using a better technique can sometimes get rid of the child's resistance. Doctors can sometimes replace a bad-tasting ...

Personalized medicine is a therapeutic approach involving the use of an individual’s genetic and epigenetic information to tailor drug therapy or preventive care. Two-step Mendelian ...

Zydus received FDA approval to conduct a Phase 2b trial testing usnoflast, its oral therapy for ALS, in 210 patients.